Renal Cell Carcinoma | Clinical

ICIs Show Improved Survival Over Targeted Therapies in Advanced Non–Clear Cell RCC

April 20, 2021

As a class, immune checkpoint inhibitor-based regimens outshine select targeted therapies in overall survival in patients with metastatic non–clear cell renal cell carcinoma.

Immuno-Oncology/TKI Combinations Take the Lead in Frontline RCC Therapy

April 18, 2021

Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.

NCCN Guidelines for RCC Add Frontline Lenvatinib/Pembrolizumab as Preferred Treatment Option

April 17, 2021

Recent updates to the National Comprehensive Cancer Network’s guidelines for renal cell carcinoma reflect quick integration of new agents and combination regimens to provide patients with RCC with more treatment options and the most up-to-date options.

Roundtable Discussion: Choueiri Leads Debate on Second-line Therapy in Patients with RCC

April 09, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, lead a debate with a group of peers on second-line therapy options for patients with renal cell carcinoma.

Adjuvant Pembrolizumab Prolongs Disease-Free Survival in Renal Cell Carcinoma

April 08, 2021

Treatment with pembrolizumab led to improvement in disease-free survival in patients with renal cell carcinoma following nephrectomy or following nephrectomy and resection of metastatic lesions, meeting the primary end point of the pivotal phase 3 KEYNOTE-564 trial.

Upcoming Trials Show Promise With Cabozantinib in RCC

April 08, 2021

Matthew T. Campbell, MD, MS, discusses trials investigating cabozantinib in patients with renal cell carcinoma.

CLEAR Study Highlights Promise of I/O and TKI Regimens in Advanced RCC

April 02, 2021

In an interview with Targeted Oncology, Thomas Hutson, DO, PharmD, reviewed findings from the CLEAR study and how these data are set to re-shape the treatment landscape of advanced renal cell carcinoma.

Higher Lenvatinib Dose May Improve HRQoL in RCC

April 02, 2021

The standard dose of lenvatinib, 18 mg per day, demonstrated an improved health-related quality of life and a longer time to deterioration over a lower starting dose of lenvatinib, 14 mg per day, in patients with renal cell carcinoma, according to secondary results from a phase 2 trial.

Expert Insights on the Evolving Treatment Paradigm During Kidney Awareness Month

March 29, 2021

In an interview with Targeted Oncology, Walter M. Stadler, MD, discussed recent updates and changes in the kidney cancer landscape, including treatment with HIF and VEGFR inhibitors.

What’s Next for Advanced RCC?

March 29, 2021

A look toward the future treatment of advanced renal cell carcinoma.